E.A. Pronkin

FSBEI HE RNSMU n.a. N.I. Pirogov of RMH, Moscow
Erectile dysfunction (ED) is one of the most common problems in urology. Despite the fact that ED is not life-threatening condition, the appearance of sexual disorders leads to rapid personal and social maladjustment of the patient. Currently, European Association of Urology and American Urological Association recommend phosphodiesterase type 5 (PDE-5) inhibitors as first line therapy for patients with ED. Given the safety profile and the lack of convincing evidence of drug dependence, as well as the self-confidence of man against the backgeound of use of sildenafil (Dynamico), the drug can be considered as one of the leading drug in the treatment of ED. Chronic use of Dynamico by certain group of patients can be considered a way of maintaining a adequate quality of life.

About the Autors

Corresponding author: E.A. Pronkin – PhD, Assistant Professor at the Department of Urology FSBEI HE RNSMU n.a. N.I. Pirogov of RMH, Moscow; e-mail:

Similar Articles

Бионика Медиа